Aptevo Therapeutics Inc (APVO) — Cash Flow-to-Debt Ratio
Aptevo Therapeutics Inc (APVO) has a Cash Flow-to-Debt Ratio of -0.53x as of December 2025, meaning its operating cash flow of $-5.24 Million could theoretically repay -1% of its total liabilities ($9.81 Million) in one year. See APVO FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Aptevo Therapeutics Inc Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Aptevo Therapeutics Inc across 12 annual periods. Also explore APVO shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Aptevo Therapeutics Inc (2014–2025)
Year-by-year debt coverage analysis for Aptevo Therapeutics Inc. For market capitalisation and broader financial context, see how much is Aptevo Therapeutics Inc worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.61x | $-25.59 Million | $9.81 Million | ▼ -18.8% |
| 2024 | -2.19x | $-23.79 Million | $10.84 Million | ▼ -136.2% |
| 2023 | -0.93x | $-11.73 Million | $12.62 Million | ▲ +28.2% |
| 2022 | -1.29x | $-21.02 Million | $16.24 Million | ▼ -230.7% |
| 2021 | -0.39x | $-21.68 Million | $55.38 Million | ▲ +50.7% |
| 2020 | -0.79x | $-29.32 Million | $36.95 Million | ▲ +22.2% |
| 2019 | -1.02x | $-42.38 Million | $41.57 Million | ▲ +26.5% |
| 2018 | -1.39x | $-51.42 Million | $37.09 Million | ▼ -16.6% |
| 2017 | -1.19x | $-41.57 Million | $34.97 Million | ▼ -33.2% |
| 2016 | -0.89x | $-36.86 Million | $41.29 Million | ▲ +56.4% |
| 2015 | -2.05x | $-48.76 Million | $23.84 Million | ▼ -10.4% |
| 2014 | -1.85x | $-47.01 Million | $25.36 Million | — |